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1. Introduction  
Patients can be exposed to a variety of potentially life threatening acute inflammations 
mainly sepsis, which accounts to 9% of all death in the US. The prevalence of non-alcoholic 
fatty liver disease (NAFLD) is about 30% in the general population. Fatty liver is known to 
be more sensitive to endotoxins. It has been reported that metabolic aspects of sepsis and 
endotoxemia are suppression of the fatty acid beta-oxidation pathway and severe 
hypoglycemia. This can be due to lipotoxic effects following accumulation of free fatty acids 
in the liver and suppression of gluconeogenesis. In this chapter we will review the 
published facts about the development of hypoglycemic effects during sepsis and the 
possible connection of such an effect to the dysregulation of lipid metabolism. Secondly a 
possible redox related antilipotoxic cellular mechanism will be suggested. Such mechanism 
can alleviate the endotoxic hypoglycemic effect and is related to nitric oxide signaling. Nitric 
oxide signaling has been demonstrated to regulate the metabolic status of cells including 
upregulation of mitochondrial biogenesis, promoting liver glucose production and 
depending on the biological setting to protect cells against accumulation of oxidative 
damage, all possibly protect against development of hypoglycemia following liver injury.  
2. Non-alcoholic fatty liver disease 
2.1 Introduction  
Non-alcoholic fatty liver disease NAFLD comprises a spectrum of hepatic pathology, 
ranging from simple steatosis (SS), in which there is an increase of fat accumulation in 
hepatocytes, through steatohepatitis to cirrhosis (Farrell, GC et al., 2008). Primary NAFLD is 
associated with obesity, insulin resistance and metabolic syndrome, diabetes and 
dyslipidemia, while secondary NAFLD is associated with all forms of liver damage 
including viral infections autoimmune and heradetory disease, drugs, toxins and nutrition 
(parenteral nutrition , B12/folic acid deficiency etc.) (Musso, G et al., 2010) (Figure 1). 
Nonalcoholic steatohepatitis (NASH) is a progressive lesion in which steatosis is 
accompanied by hepatocyte injury and death, as well as hepatic infiltration by inflammatory 
cells. NASH-related liver damage often triggers liver fibrosis. In severe cases, NASH may 
progress to cirrhosis and possibly hepatocellular carcinoma (Lim, JH et al., 2006). NAFLD is 
one of the most common liver diseases worldwide, affecting all racial, ethnic, and age 
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groups without sex predilection. The prevalence of NAFLD is around  30 % of the general 
population (Musso, G et al., 2009; Musso, G et al., 2010), NASH affects about 3 percent of the 
lean population (those weighing less than 110 percent of their ideal body weight), 19 percent 
of the obese population, and almost half of morbidly obese people. It is estimated about that 
8.6 million obese adult Americans may have NASH and about 30.1 million may have the 
simple steatosis. Thus, the very high prevalence of fatty liver means that this disorder will 
contribute significantly to an increased burden of ill-health at the present and in the future 
(Farrell, GC et al., 2008). 
NAFLD refers to the presence of hepatic stetosis not associated with a significant intake of 
alcohol (Adams, LA & KD Lindor, 2007) and its incidence is paralleling the increasing 
numbers of overweight and obese individuals worldwide (Yan, E et al., 2007). When fat 
accounts for more than 10% of liver’s weight, then the condition is called fatty liver and it 
can develop more serious complications (American Liver Foundation). Fatty liver may cause 
no damage, but the excess fat leads to inflammation causing liver damage is refered to as 
steatohepatitis (American Liver Foundation). The term nonalcoholic steatohepatitis (NASH) 
was first coined by Ludwig et al at 1980 (Ludwig, J et al., 1980) describing the pathology of 
20 patients histologically similar with alcoholic hepatitis but without the history of alcohol 
abuse. Sometimes, inflammation from a fatty liver is linked to alcohol abuse; this is known 
as alcoholic steatohepatitis (ASH). Otherwise the condition is called NASH (American Liver 
Foundation). NAFLD comprises a spectrum of liver pathology including bland steatosis, 
steatohepatitis, cirrhosis (Yang, L & A Diehl, 2007) and hepatocellular carcinoma (Angulo, P, 
2007) where most liver related morbidity and mortality occur. The histological damage in 
NAFLD is very similar to that seen in patients with alcoholic liver disease (ALD), but 
NAFLD is by definition not alcohol induced (Angulo, P, 2007).  
NAFLD is the most common chronic liver disease in the western world (Adams, LA & KD 
Lindor, 2007). Sedentary lifestyle and poor dietary choices are leading to a weight gain 
epidemic in westernized countries, subsequently increasing the risk for developing the 
metabolic syndrome and NAFLD (Rector, RS et al., 2008). Although, NAFLD may be 
categorized as primary and secondary depending on the underlying pathogenesis both type 
of NAFLD can be interrelated (Figure 1). 
 
 
Fig. 1. Type and causes of NAFLD. Primary and secondary NAFLD may be interrelated. 
Induction of liver damage with may lead to fat accumulation in the liver  may exacerbate  
primary NAFLD under conditions of hyperlipidemic, on the other hand primary NAFLD 
can increase the vulnerability of the liver to different kind of stressors and damaging agents. 
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2.2 Epidemiology 
NAFLD is increasingly being recognized as an important and common condition, affecting 
approximately 20-45% of the general population (Joy, D et al., 2003) in different countries. It 
is estimated to affect approximately 30% of the general US population and is considered the 
hepatic manifestation of the metabolic syndrome (Rector, RS et al., 2008; Zivkovic, AM et al., 
2007). According to (Angulo, P, 2007), NAFLD affects one in three adults and one in 10 
children in the United States. Although NAFLD typically occurs between the fourth and six 
decades of life (Targher, G et al., 2007; Zhou, YJ et al., 2007), it is known to affect children as 
well as adults and is not considered discriminatory to age (Imhof, A et al., 2007; Zhou, YJ et 
al., 2007). Many studies have found a wide discrimination of NAFLD between the sexes 
(Amarapurkar, D et al., 2007; Zelber-Sagi, S et al., 2006).  
Among different ethnic groups, however, the picture becomes a bit more complicated. 
Browning et al (Browning, JD et al., 2004) reported that the prevalence of fatty liver was 
highest in Hispanics (45%) compared to Caucasians (33%) or African Americans (24%) 
which introduced the possibility of race related variability in the susceptibility to NAFLD. 
Furthermore, within specific race, such as Caucasians, sex-related differences in the presence 
of fatty liver (42% in men and 24% in women) had been observed, which indicates the risk 
factors for NAFLD may vary depending on ethnicity and sex (Browning et al, 2004).   
Among 3543 peoples, surveyed in South China, 609 (17.2%) were diagnosed having fatty 
liver disease (FLD, 23.0% in urban and 14.5% in rural) out of which prevalence of NAFLD 
was 15.5% (Zhou, YJ et al., 2007). In the same study, prevalence of FLD among the children 
at the age of 7-18 years was 1.3% with all having NAFLD. The prevalence and incidence of 
NAFLD is expected to increase worldwide as the global obesity epidemic spreads and the 
trend in developing countries toward the western lifestyle continues (Angulo, P, 2007). 
2.3 Clinical aspects of NAFLD 
Most patients with NAFLD have no symptoms or signs of liver disease at the time of 
diagnosis (Angulo, P & KD Lindor, 2002). NAFLD has been characterized with 
asymptomatic elevation of aminotransferases, radiological findings of fatty liver or 
unexplained persistent hepatomegaly (Angulo, P & KD Lindor, 2002). NAFLD patients may 
be complaint of fatigue or a sensation of fullness or discomfort in the right upper abdomen . 
Hepatomegaly is one of the more consistent physical findings, described in up to 75% of 
patients with NAFLD (Yan, E et al., 2007). Other findings on physical examination that may 
suggest NAFLD as the cause of liver abnormalities include those characterizing insulin 
resistance and metabolic syndrome, such as central obesity, hypertriglyceridemia, and 
hypertension (Yan, E et al., 2007).  
The most common and often the only laboratory abnormality found in NAFLD patients, is 
mild to moderate elevation of liver enzymes (Angulo, P, 2007; Angulo, P & KD Lindor, 2002) 
alanine aminotransferase (ALT) and aspartate aminotransferase (AST): defined as ALT>45 
U/L, AST>45 U/L or γ Glutamyl transferase (GGT) >50 U/L (Hickman, I et al., 2008)In the 
patients with FLD, AST/ALT ratio is usually less than one, but this ratio increases as fibrosis 
advances (Angulo, P, 2007). A study on Japanese adults showed that triglycerides, total 
protein albumin, AST and ALT were all significantly higher while high density lipoprotein 
(HDL) cholesterol and AST/ALT ratio were significantly lower in subjects with NAFLD 
than those without fatty liver (Jimba, S et al., 2005).  
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3. Association of fatty liver with hypoglycemia 
3.1 Fatty acid oxidation defects 
Adipocytes have the unique capacity to store excess fatty acids in the form of TGs in lipid 
droplets. Non-adipose tissues, such as hepatocytes, cardiac myocytes and pancreatic beta-cells, 
have a limited capacity for lipid storage. In hyperlipidemic states, the accumulation of excess 
lipid in non-adipose tissues can lead to cellular dysfunction and/or cell death, a phenomenon 
known as lipotoxicity (Listenberger, LL et al., 2003; Unger, RH, 1995; Weinberg, JM, 2006). 
Most studies attribute strong lipiotoxic effects to free fatty acids (FFAs). Lipotoxic effects in the 
liver include disruption of liver-cell function (Alkhouri, N et al., 2009).  
The connection between increased levels of fatty acids to hypoglycemia is known in genetic 
diseases of fatty acid oxidation defects (Figure 2). Inherited defects in mitochondrial fatty- 
acid beta-oxidation comprise a group of at least 12 diseases characterized by distinct enzyme 
or transporter deficiencies. Most of these diseases have a variable age of onset and clinical 
severity. Symptoms are often episodic and associated with mild viral illness, physiologic  
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Fig. 2. Classical theory of how biochemical fatty acid oxidation defects generate 
hypoglycemic phenotype   
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stress, or prolonged exercise that overwhelms the ability of mitochondria to oxidize fatty 
acids. Depending on the specific genetic defect, patients develop fasting hypoketotic 
hypoglycemia, cardiomyopathy, rhabdomyolysis, liver dysfunction, or sudden death 
(Kompare, M & WB Rizzo, 2008). Medium-chain acyl-CoA deshydrogenase (MCAD) 
deficiency is the most frequent disorder of mitochondrial fatty acid oxidation (Baruteau, J et 
al., 2009), The pathophysiology of these diseases is still not completely understood, 
hampering optimal treatment (Houten, SM & RJ Wanders). Hypoglycemia as one major 
clinical sign in all fatty acid oxidation defects and occurs due to a reduced hepatic glucose 
output and an enhanced peripheral glucose uptake (Spiekerkoetter, U & PA Wood). A 
connection of such disorders-phenotype with metabolic derangement that are not 
necessarily related to genetic defected has been demonstrated recently via  the Sirtuins. 
Sirtuin 3 (SIRT3) is localized in the mitochondrial matrix, where it regulates the acetylation 
levels of metabolic enzymes, including acetyl coenzyme A synthetase 2. Mice lacking SIRT3 
exhibit hallmarks of fatty-acid oxidation disorders during fasting  (Hirschey, MD et al.).  
3.2 Liver regeneration 
The liver is known for its regenerative capacity. It is now well accepted that there are two 
physiological forms of regeneration in the liver as responses to different types of liver injury. 
The first line for regeneration are mature, normally quiescent adult hepatocytes. During mild 
liver injury due to drugs, toxins, resection, or acute viral diseases, hepatocytes are the main cell 
type to proliferate and regenerate the liver. The mature hepatocytes have relatively low 
proliferative capacity. The second line of defense are the progenitor cell population, that are 
activated when injury is severe, or when the mature hepatocytes can no longer regenerate the 
liver due to senescence or arrest (Riehle, KJ et al., 2011). The metabolic requirements of the 
generating liver form Partial hepatectomy (PH) of from liver damage are impressive. There is a 
need to activate Kupffer cells in order to initiate the regenerating cascade. For these reasons  
increased accumulation of insulin independent glucose utilization is needed which may cause 
plasma glucose utilization due to the high metabolic demend. Impaired regenerative capacity 
of fatty livers might promote the progression of nonalcoholic fatty liver disease (NAFLD). 
Partial hepatectomy (PH) activats oxidant-sensitive, growth-regulatory kinase cascades which 
is abnormal in fatty hepatocytes. The normal coordinated induction of Jun N-terminal kinases 
(Jnks) and extracellular regulated kinases (Erks) does not occur after PH in ob/ob mice.  This is 
associated with enhanced activation of Akt, which inhibits phosphoenolpyruvate 
carboxykinase (PEPCK) induction, causing severe hypoglycemia and increased lethality in the 
ob/ob group (Yang, SQ et al., 2001).  
4. Alcoholic liver injury 
4.1 Introduction 
The liver breaks down alcohol so that it can be eliminated from our body. When alcohol is 
over consumed than the liver can process, the resulting imbalance can injure the liver by 
interfering with its normal breakdown of proteins, fats, and carbohydrates (American Liver 
Foundation). ALD is a common consequence of long term alcohol abuse (Zeng, MD et al., 
2008) and represents a major cause of mortality and morbidity worldwide (Albano, E, 2008; 
Bergheim, I et al., 2005). ALD encompasses a broad spectrum of morphological features 
ranging from simple steatosis with minimal injury to more advanced stage liver injury, 
including alcoholic steatohepatitis, alcoholic fibrosis and alcoholic cirrhosis (Albano, E, 2008; 
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Zeng, MD et al., 2008). The risk of steatosis, inflammation and fibrosis are more common in 
alcoholics and increases with time and the amount of ethanol consumed (Vidali, M et al., 
2008).  
4.2 Clinical aspects of ALD 
Fatty liver, the most common syndrome of ALD, is characterized by the excessive 
accumulation of fat inside hepatocytes (Adachi, M & DA Brenner, 2005). Indeed the 
excessive fat accumulation in the hepatocytes is the most common and earliest response of 
the liver to chronic alcohol consumption (Song, Z et al., 2008). Morphological criteria of 
steatohepatitis are steatosis, ballooning of hepatocytes, pericellular fibrosis and 
inflammation (Denk, H et al., 2005). In an animal model of ALD, rats exposed 4 weeks to 
alcohol exhibited a significant increase in liver to body weight ratio, serum ALT levels and 
hepatic TNF- α compared to control group (Song, Z et al., 2008). Tabassum, F et al. 
(Tabassum, F et al., 2001) found that the levels of alkaline phosphate, ALT, protein and 
globulin were significantly increased in alcoholic males compared to control subjects. The 
AST/ALT ratio is significantly higher in ALD patients sometimes even higher than two 
(Adachi, M & DA Brenner, 2005). 
4.3 Ethanol metabolism and role of acetaldehyde 
There are multiple mechanisms for the development and progression of ALD (Figure 3) and 
many of these mechanisms interact to each other (Barve, A et al., 2008).  
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Fig. 3. Mechanisms for the development of non-alcoholic fatty liver disease  
ALD has a complex pathogenesis, in which acetaldehyde; the major ethanol metabolite 
plays a central role (Lieber, CS, 1997). Alcohol is primarily metabolized by the successive 
oxidative activities of alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase 
(ALDH), Figure 4, (Hasse, J & L Matarese, 2004; Lumeng, L & DW Crabb, 2001). Ethanol is 
metabolized mainly in the hepatocytes in three different sites: cytosol, endoplasmic 
reticulum, peroxisome and mitochondria (De Minicis, S & DA Brenner, 2008). According to 
(Lieber, CS, 1997) the main pathway involves cytoplasmic ADH which catalyzes the 
oxidation of ethanol to acetaldehyde then oxidized to acetate by the mitochondrial ALDH. 
Most of acetate is released into the blood (Hasse, J & L Matarese, 2004). According to 
Novitskiy, G et al (Novitskiy, G et al., 2006) acetaldehyde enhances the formation of ROS. 
According to (Lieber, CS, 1997), sever toxic manifestations are produced by an accessory 
inducible pathway, the microsomal ethanol-oxidizing system (MEOS) in endoplasmic 
reticulum involving an ethanol-inducible CYP2E1 in which the oxidation of ethanol to 
acetaldehyde and acetate also leads to generation of ROS [hydroxyethyl free radicals, 
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hydrogen peroxides (H2O2) and super oxide anion (O2-)]. High reduced nicotinamide 
adenine dinucleotide (NADH) is produced due to alcohol metabolism leading to high 
NADH/NAD+ ratio which overrides the cell’s ability to maintain normal redox state (Hasse, 
J & L Matarese, 2004).  
The lactic acid cannot be converted into pyruvate due to lack of NAD+ leading to 
hyperlacticacedemia (Hasse and Matarese, 2004). They also reported that tricarboxylic acid 
cycle (TCA) is also diminished because; in one hand it requires a lot of NAD+ and on the 
other hand the excess NADH inhibits two regulatory enzymes isocitrate dehydrogenase and 
α-ketoglutarate dehydrogenase, as a consequence acetyl coenzyme A (CoA) is accumulated. 
The mitochondria in turn use hydrogen produced from the ethanol metabolism as a fuel 
source and all these activities lead to decreased fatty acid oxidation and accumulation of 
triglycerides in the hepatocytes (Hasse, J & L Matarese, 2004). They also reported that 
malnutrition can also occur in early alcoholic liver disease due to the suppression of TCA 
cycle coupled with decreased gluconeogenesis due to ethanol.  
 
Endoplasmic 
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Fig. 4. Ethanol metabolism in hepatocytes. These mechanisms are potentially involved in 
oxidative stress production. Ethanol is metabolized in acetaldehyde and then transformed 
into acetate, as shown. 
Chronic ethanol consumption increases fatty acid synthesis by inducing the expression of 
lipogenic enzymes which are regulated by transcription factor SREBP (Adachi, M & DA 
Brenner, 2005). Chronic ethanol consumption significantly inhibits mitochondrial ALDH 
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activity while the rate of ethanol oxidation to acetaldehyde is even enhanced, resulting in 
striking increase in tissue and plasma levels of acetaldehyde which results in metabolic 
disturbances, such as hyperlactacidemia, acidosis, hyperglycemia, hyperuricemia and fatty 
liver (Lieber, CS, 1997). However, in many cases  Alcohol consumption can generate a life 
threatening hypoglycemia.  
5. ALD and hypoglycemia 
Alcohol consumption may have beneficial as well as deadly consequences. It is generally 
considered that alcohol consumption interferes with all three glucose sources and with the 
actions of the regulatory hormones. Chronic heavy drinkers often have insufficient dietary 
intake of glucose. Without eating, glycogen stores are exhausted in a few hours (Gordon, 
GG & CS Lieber, 1992). In addition, the body's glucose production is inhibited while alcohol 
is being metabolized (Sneyd, JGT, 1989). The combination of these effects can cause severe 
hypoglycemia 6 to 36 hours after the drinking episode (1).  Even in well-nourished people, 
alcohol can disturb blood sugar levels. Acute alcohol consumption, especially in 
combination with sugar, augments insulin secretion and causes temporary hypoglycemia 
(O'Keefe, SJ & V Marks, 1977). In addition, studies in healthy subjects and insulin-dependent 
diabetics  have shown that acute alcohol consumption can impair the hormonal response to 
hypoglycemia. Alcohol consumption can be especially harmful in people with a 
predisposition to hypoglycemia, such as patients who are being treated for diabetes. Alcohol 
can interfere with the management of diabetes in different ways. Acute as well as chronic 
alcohol consumption can alter the effectiveness of hypoglycemic medications. Treatment of 
diabetes by tight control of blood glucose levels is difficult in alcoholics, and both 
hypoglycemic and hyperglycemic episodes are common. In a Japanese study, alcoholics 
with diabetes had a significantly lower survival rate than other alcoholics (Judith Fradkin, 
MD, 1994). A recent meta analysis indicated beneficial effect of moderate alcohol 
consumption reduces the incidence of type 2 diabetes (T2D), however, binge drinking seems 
to increase the incidence. Acute intake of alcohol does not increase risk of hypoglycemia in 
diet treated subjects with T2D, only when sulphonylurea is co-administered. Long-term 
alcohol use seems to be associated with improved glycemic control in T2D probably due to 
improved insulin sensitivity (Pietraszek, A et al., 2010). The capacity of alcohol to shift its 
activity from beneficial to deleterious could be related to other factors that are related to 
impairment in lipid metabolism. 
ALD has been suspected known to generate the sudden death syndrome in alcoholic 
individuals. Two major factors have been considered contributory to ethanol-induced 
hypoglycaemia (Arky, RA & N Freinkel, 1966; Madison, LL, 1968) suppression of hepatic 
gluconeogenesis resulting from an increase in the NADH/NAD+ ratio accompanied by 
enhanced ethanol metabolism, and depletion of hepatic glycogen storage secondary to 
starvation. In cases of alcohol-related sudden deaths hydroxybutyrate levels are 
significantly elevated. Platia and Hsu (Platia, EV & TH Hsu, 1979)) described five non-
diabetic alcohol abusers with hypoglycaemic coma and ketoacidosis and contended that the 
combination of alcohol-related hypoglycaemia and ketoacidosis may be common.  
Part of the pathogenesis of the widely known syndrome of sudden death with hepatic fatty 
metamorphosis observed in alcohol abusers was described by Yuzuriha et al. (Yuzuriha, T et 
al., 1997), 11 subjects who died under such circumstances between 1987 and 1993 were 
scrutinized both for clinical and pathological data. Death occurred followed several days of 
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uninterrupted drinking often with little dietary intake. Most of these individuals suffered 
from severe hypoglycemia. The common hepatic pathology was the extensive appearance of 
numerous microvesicular fatty droplets in the hepatocytes together with varying degrees of 
macrovesicular fatty change; four subjects had an underlying cirrhosis. Death undoubtedly 
results from a variety of metabolic disturbances triggered by the combination of massive 
ethanol intake and starvation. The appearance of extensive microvesicular fatty change 
superimposed on macrovesicular fatty change was considered to be an associated 
phenomenon. The most striking findings in the liver were extensive microvesicular fatty 
change within hepatocyte and the presence of megamitochondria. 
6. Ischemic hepatitis 
Ischemic hepatitis also known Hypoxic hepatitis or shock liver, can be characterized by 
necrosis of the zone 3 hepatocytes and significant increase in serum aminotransferase levels. 
It is the consequence of multiorgan injury. Outcome is influenced by the severity of liver 
impairment and the etiology and severity of the basic disease (Fuhrmann, V et al., 2009).The 
syndrome occurs under conditions of clinical setting of cardiac, circulatory or respiratory 
failure. It is recognized as the most frequent cause of acute liver injury with a reported 
prevalence of up to 10% in the intensive care unit (Fuhrmann, V et al., 2010). Patients with 
ischemic hepatitis and vasopressor therapy have a significantly increased mortality risk in 
the medical intensive care unit population. Ischemic hepatitis causes several complications 
including spontaneous hypoglycemia which can be considered secondary to impairment of 
gluconeogenic response in the exhausted liver (Fuhrmann, V et al., 2010; Fuhrmann, V et al., 
2009; Nomura, T et al., 2009). 
7. Sepsis  
7.1 Introduction 
Definition "Systemic Inflammatory Response Syndrome or (SIRS) is evidence of the body's 
ongoing inflammatory response. When SIRS is suspected or known to be caused by an 
infection, this is sepsis. Severe sepsis occurs when sepsis leads to organ dysfunction, such as 
trouble breathing, coagulation or other blood abnormalities, decreased urine production, or 
altered mental status. If the organ dysfunction of severe sepsis is low blood pressure 
(hypotension), or insufficient blood flow (hypoperfusion) to one or more organs (causing, 
for example, lactic acidosis), this is septic shock. Sepsis can lead to multiple organ 
dysfunction syndrome (MODS) (formerly known as multiple organ failure), and death. 
Organ dysfunction results from local changes in blood flow, from sepsis-induced 
hypotension (< 90 mmHg or a reduction of ≥ 40 mmHg from baseline) and from diffuse 
intravascular coagulation, among other things. 
Sepsis can be defined as the body's response to an infection. An infection is caused by 
microorganisms or bacteria invading the body and can be limited to a particular body 
region or can be widespread in the bloodstream. Sepsis is acquired quickest with infections 
developed in surgery and physical contact with someone with sepsis. 
Bacteremia is the presence of viable bacteria in the bloodstream. Likewise, the terms viremia 
and fungemia simply refer to viruses and fungi in the bloodstream. These terms say nothing 
about the consequences this has on the body. For example, bacteria can be introduced into 
the bloodstream during toothbrushing. This form of bacteremia almost never causes 
problems in normal individuals. However, bacteremia associated with certain dental 
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procedures can cause bacterial infection of the heart valves (known as endocarditis) in high-
risk patients. Conversely, a systemic inflammatory response syndrome can occur in patients 
without the presence of infection, for example in those with burns, polytrauma, or the initial 
state in pancreatitis and chemical pneumonitis" (wikipedia). 
Severe sepsis is a significant cause of mortality worldwide. Current research estimates that 
more than 9% of all deaths in the US can be attributed to severe sepsis. Experimental 
evidence shows that the liver is an important target organ in the development of multiple 
organ dysfunction during sepsis (Koo, DJ et al., 1999; Koo, DJ et al., 2000). Due to its major 
role in metabolism and host-defense mechanisms, the liver is pivotal in participating in the 
systemic response to severe infection, because it contains the largest mass of resident 
macrophage Kupffer cells (KC) in the body, making up approximately 15% of the liver cells 
(Szabo, G et al., 2002). KC are highly relevant in the inflammatory response to bacterial 
infection and non-bacterial inflammation by 1) playing a major role in both clearance and 
detoxification, e.g. removal of LPS from the circulation (especially the portal vein) and 2) 
producing inflammatory mediators (Van Amersfoort, ES et al., 2003).  
8. Sepsis and hypoglycemia 
8.1 The use of intensive insulin therapy (IIT) to maintain normal blood glucose levels 
in septic patients 
At 2001 van den Berghe and colleagues published the clinical implications of tight 
euglycemic control (van den Berghe, G et al., 2001). This observation significantly and 
rapidly changed intensive care unit (ICU) practice. It has been suggested that insulin 
administered to maintain glucose at levels below 110 mg/dl decreased mortality, the 
incidence of infections, sepsis, and sepsis-associated multiorgan failure in surgical patients, 
reduced kidney injury, and accelerated weaning from mechanical ventilation and discharge 
from the ICU in medical patients. However, current evidences suggest that the tight 
euglycemic control which is implemented in intensive care units around the world could be 
detrimental. Increasing evidence suggest that tight euglycemic control is which is associated 
with development of hypoglycemia has detrimental outcomes (Brunkhorst, FM et al., 2008; 
Jeschke, MG et al., 2010).Therefore, In practice regulating blood glucose levels  is 
recommended to target glucose level below 8.3 mmol/L. This is indicated for the 
management of severe sepsis by the Surviving Sepsis guidelines (Orford, NR, 2006) 
The main problem with IIT is the risk of development of hypoglycemia. The recent trials 
reporting reduced morbidity and mortality in critically ill patients treated with IIT require 
careful examination, including the subsequent post-hoc analyses. An understanding of the 
molecular and metabolic mechanisms by which IIT may be beneficial and the evidence that 
it benefits patients with severe sepsis, and a review of the risks of hypoglycaemia are also 
necessary when deciding whether to implement IIT in severe sepsis. Patients with severe 
sepsis are likely to benefit from IIT based on metabolic effects and their prolonged stays in 
the intensive care unit. All together, The current evidence suggests IIT should be 
implemented, aiming for the lowest glycaemic range that can be safely achieved while 
avoiding hypoglycaemia. 
8.2 Development of hypoglycemia in septic patients without IIT 
The severity of sepsis is shown to correlate with the risk of sustaining hyperglycemia as well 
as critical hypoglycemia (Krinsley, JS, 2008). Hypoglycemia during hospitalization occurs in 
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patients with and without diabetes. In elderly hospitalized patients a predicted increase in-
hospital 3- and 6-month cumulative mortality has been documented (Kagansky, N et al., 
2003).  In addition, sepsis is 10 times more common in these patients than in non-
hypoglycemic patients. Previously, it has been shown that features of hepatitis and steatosis 
are the primary histological findings in the liver of patients dying from sepsis (Koskinas, J et 
al., 2008). The hypoglycemic effect due to fatty liver is also a known phenomenon in 
alcoholic patients and is related to the fatty liver sudden death syndrome (Denmark, LN, 
1993; Randall, B, 1980; Yuzuriha, T et al., 1997). Altogether, the accumulated data suggest 
that although fatty liver and inflammation can generate a phenotype of insulin resistance, it 
can also lead to severe hypoglycemic life-threatening situations in patients with steatosis 
and acute inflammation due to an increase in hepatic insulin sensitivity (Thompson, BT, 
2008; van der Crabben, SN et al., 2009). The mechanism(s) for hypoglycemia with sepsis is 
not well defined. Depleted glycogen stores, impaired gluconeogenesis and increased 
peripheral glucose utilization may all be contributing factors. Incubation of bacteria in fresh 
blood at room temperature does not increase the normal rate of breakdown of glucose 
suggesting that the hypoglycemia occurs in vivo by increased glucose utilization or by a 
decrease in glucose production. Hypoglycemia is an important sign of overwhelming sepsis 
(Miller, SI et al., 1980).  Fischer et al” have reported that hypoglycemic episodes in 
nondiabetics were associated with infection and septic shock. The majority of cases of 
hypoglycemia reported in their study were related to liver disease, infections, shock, 
pregnancy, neoplasia, or burns. Hypoglycemia was not the apparent cause of death in any 
patient, but the overall hospital mortality was 27 percent and was related to the degree of 
hypoglycemia and the number of risk factors for hypoglycemia (Fischer, KF et al., 1986).  
In 1991 Charles et al have studied the mechanism by which infection can lead to 
hypoglycemia. A hypermetabolic septic state was produced in rats by subcutaneous 
injections of live Escherichia coli.  Sepsis increased whole body glucose disposal by 53% 
under basal euglycemic conditions and this increase resulted from an enhanced rate of 
glucose removal by liver, spleen, lung, ileum, and skin.  In sepsis, the rate of non-insulin-
mediated glucose uptake (NIMGU) was46% higher than in nonseptic animals. Severe 
hypoglycemia (2 mmol/L) produced a relative insulin deficiency and decreased whole body 
glucose disposal in both septic and nonseptic animals by 53% to 56%. Compared with 
euglycemic insulinopenic animals. The decrease in blood glucose decreased glucose uptake 
by all tissues examined, except brain and heart. However, sepsis still increased glucose 
uptake by liver, spleen, lung, ileum, and skin (25% to SO%), compared with hypoglycemic 
nonseptic rats. Therefore, the conclusion of the study was that sepsis increases NIMGU 
under basal conditions due to an increased glucose uptake by macrophage-rich tissues, and 
that this enhanced rate is maintained during hypoglycemia (Lang, CH & C Dobrescu, 1991). 
It is therefore suggested that during sepsis there is increased glucose utilization by 
macrophages-rich tissues, which may lead to hypoglycemia. However, there is also a strong 
connection between the liver capacity to generate glucose and the development of 
hypoglycemia. A case report which connect hypoglycemia with sepsis and liver disease was 
reported at 1994 in Japan. A 78-year-old woman that was admitted to a hospital because of 
disturbance of consciousness. On admission, the body temperature was 35.5 degrees C and 
systolic blood pressure was 50 mmHg. Ascites and semicomatose consciousness were 
detected. Laboratory evaluation demonstrated the following values: leukocyte count 
38800/microliters, blood sugar 3 mg/l and arterial blood pH 6.9. Therapy with 
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catecholamine and antibiotics was started, but she expired 10 hours after admission. 
Bacteroides ovatus was detected from her blood. Autopsy findings disclosed the connection 
to advance liver disease  and indicated abscess and perforation of the uterus, and liver 
cirrhosis (Suzuki, A et al., 1994). It is known that Sepsis suppresses fatty acid oxidation, It 
has been reported that fatty acid oxidation is significantly suppressed under conditions of 
sepsis and endotoxemia. During the acute-phase response, fatty acid oxidation decrease is 
associated with hypertriglyceridemia. LPS was demonstrated to suppress FFAs oxidation, 
and consequently contributes to elevated plasma levels of FFAs and TGs. LPS suppresses 
FFAs oxidation through decreasing the expression levels of key FFA oxidative genes 
including CPT-1 and MCAD in both liver and kidney tissues. LPS has been shown to 
selectively suppress the levels of PPARalpha and PGC-1alpha in tissues (Maitra, U et al., 
2009). The decrease was rapid and occurred at very low doses of LPS. Similar decreases in 
levels of these genes occurred during zymosan- and turpentine-induced inflammation, 
indicating that suppression of the PGC-1alpha, and medium chain acyl coA dehydrogenase 
pathway is a general response during infection and inflammation (Kim, MS et al., 2005). We 
have demonstrated in a model of liver steatosis and endotoxemia that the expression of 
gluconeogenic enzymes and gluconeogenesis are strongly suppressed. This was 
accompanied with lowered blood glucose levels. The treated mice had a phenotype of 
insulin sensitivity with decreased blood insulin levels (Tirosh, O et al., 2010). Therefore, the 
effect of free fatty acids and triglycerids on expression of key gluconeogenic enzymes was 
studied. The effect of exposing hepatocytes to free fatty acids was to suppress the inducible 
expression of gluconeogenic enzymes Figure 5 and Figure 6. 
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Fig. 5. Inhibition of gluconeogenic response by free FAs in FaO cells. FaO cells were 
cultured and pre-treated with FAs mixture (2:1 oleate/palmitate with 1% BSA) or with FAs-
Br mixture (2:1 oleate/2-Bromopalmitate with 1% BSA) to final concentration of 1mM FAs. 
After that, dexamethasone (1μM) was added to cells media for 6 hours. mRNA expression 
levels of PEPCK was measured by quantitative real-time RT-PCR. Means with different 
letters differ at P<0.05. 
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Fig. 6. Fat accumulation in FaO cultures. FaO cells were cultured and exposed to FAs 
mixture (2:1 oleate/palmitate with 1% BSA) at different concentrations for 18 hours (A) or to 
final concentration of 1mM FAs for different times (B). Alternatively, FaO cells were 
cultured and exposed to FAs mixture (2:1 oleate/palmitate with 1% BSA) or to FAs-Br 
mixture (2:1 oleate/2-Bromopalmitate with 1% BSA) to final concentration of 1mM FAs (C). 
After that, cells were stained with Nile-Red and fluorescence was examined by FACS 
analysis. Means with different letters differ at P<0.05.  
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The mechanism for the development of hypoglycemia during sepsis and the lipid 
connection can be therefore explained by the following figure 7: 
 
 
Fig. 7. LPS and bacteria facilitate 1 ) non-insulin-mediated glucose uptake 2) release of 
triglycerides and suppression of beta-oxidation in hepatocytes therefore elevating the FFA 
levels. This results in suppression of liver glucose output capacity. The results is 
hypoglycemia. 
9. Nitric oxide as a potential antihypoglycemic agent 
9.1 Nitric oxide involvement in liver damage and sepsis 
One of the main effects of the inflammatory response in the liver is an increase in the levels 
of inducible nitric oxide synthase (iNOS). Therefore, it has been postulated that nitric oxide 
(NO) would contribute to hepatotoxicity through inhibition of ATP synthesis, increased 
reactive oxygen species (ROS), and the inability to adapt to hypoxic stress (Mantena, SK et 
al., 2008). Other studies imply that decreased production of NO from endothelial nitric 
oxide synthase (eNOS) contributes to liver pathology via dysregulation of blood flow and 
oxygen delivery (Liu, J & MP Waalkes, 2005). Furthermore, in iNOS knockout mice, 
hepatocytes undergo necrosis and apoptosis after PH, indicating that the production of NO 
is essential to protect hepatocytes from death after liver resection (Rai, RM et al., 1998).  We 
have demonstrated that a decreased in eNOS expression precedes formation of liver damage 
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following intensive blood infusion of triglycerides (TGs) in rats (Tirosh, O et al., 2009). Thus, 
it appears that NO can be both toxic or protective, depending on the acute physicological 
environment in the liver. 
In the case of sepsis, there are also contractory reports concerning the role of NO.  Although 
it has been suggested that NO is a mediator of organ dysfunction, different opinions suggest 
a protective role of NO in sepsis. Indeed, numerous reports of benefits associated with NO 
donor administration in clinical and preclinical studies of sepsis have been published 
(Lamontagne, F et al., 2008). Obesity increases sensitivity to endotoxin liver injury. It is 
known that fatty liver sensitivity to acute inflammation injury is much higher compared to 
normal livers (Yang, SQ et al., 1997). Our published studies in a mouse model of fatty liver 
and endotoxemia demonstrated a significant protective role for iNOS expression. iNOS(-/-) 
mice were found to be more sensitive to liver damage thereby supporting the hypothesis 
that iNOS has a protective effect.  Additionally, iNOS(-/-) mice with fatty liver suffered 
from severe fatal hypoglycemia after endotoxic treatment (Tirosh, O et al., 2010).  
9.2 Hyperglycemia or hypoglycemia: A paradox of inflammation, and the involvement 
of nitric oxide  
Along with a rising prevalence of non-alcoholic fatty liver disease (NAFLD), there is a 
marked increase in individuals suffering from metabolic impairments.  One widespread 
imbalance is the insulin resistance syndrome or metabolic syndrome which refers to a 
constellation of symptoms, including glucose intolerance, obesity, dyslipidemia, and 
hypertension. This syndrome is known to promote the development of type 2 diabetes, 
cardiovascular disease, cancer, and other disorders. The liver plays a major role in the 
regulation of glucose, lipid and energy metabolism, which are tightly regulated by insulin 
(Leclercq, IA et al., 2007; Raddatz, D & G Ramadori, 2007). In addition, insulin resistance is 
now recognized as a pathological factor in the development of NAFLD (Leclercq, IA et al., 
2007; Raddatz, D & G Ramadori, 2007). It has been suggested that prolonged elevation of the 
levels of sterol regulatory element binding proteins (SREBPs) is responsible for inhibition of 
insulin signaling in fatty liver (Shimano, H, 2007) and that the intracellular accumulation of 
lipids-namely, diacylglycerol-triggers activation of novel protein kinases C(PKC ) with 
subsequent impairments in insulin signaling (Samuel, VT et al.). Hepatic insulin resistance 
can be defined as the failure of insulin to adequately suppress hepatic glucose production 
(Weickert, MO & AF Pfeiffer, 2006). 
Several studies indicate the involvement of inflammatory activation in the development of 
hepatic and peripheral insulin resistance (Cai, D et al., 2005). On the other hand, acute 
inflammation induced by lipopolysaccharides (LPS) facilitates a hypoglycemic effect and 
impairment of hepatic Glucose-6 phosphatase (G6Pase) expression (Lo, YC et al., 2004; 
Maitra, SR et al., 1999; Oguri, S et al., 2002). Indeed, as metioned above in critically ill 
patients, sepsis-induced hypoglycemia is a well known event (van der Crabben, SN et al., 
2009). We showed by temporal kinetics that the rapid induction of iNOS played a role in 
counteracting hypoglycemic effect of LPS and lipids rather than exacerbating it (Tirosh, O et 
al.). NO had a direct stimulatory effect promoting liver glucose production, making iNOS 
expression necessary for survival. Experiments performed with the NO donor DETA-
NONOate in cultured hepatocytes showed a positive effect of NO on expression of 
gluconeogenic enzymes.  Our data indicate that NO generated by the iNOS protein can 
support the expression of PGC 1alpha and liver gluconeogenic genes during acute 
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inflammation. We believe that this effect is mediated by NO’s capacity to promote the 
removal of free fatty acids (FFAs). Indeed, NO was found to act as a signaling molecule that 
can activate the transcription factor co-activator PGC 1alpha facilitating mitochondrial 
biogenesis (Nisoli, E & MO Carruba, 2006; Nisoli, E et al., 2007).  
Our results that nitric oxide produced during the acute inflammatory process in fatty liver 
promotes PGC1 expression and liver glucose production supports the hypothesis that it acts 
as an antihypoglycemic factor. The lipotoxicity during acute inflammation in the fatty liver 
is manifested by increased oxidative stress and lipid peroxidation and therefore NO also 
function as an antioxidant (Kanner, J et al., 1991; Kanner, J et al., 1992; Volk, J et al., 2009) 
protecting the liver. Therefore, NO derived from inducible nitric oxide synthase (iNOS) may 
paradoxically function as an antioxidant protecting fatty liver during acute inflammation.  
This phenomenon is probably quite the reverse of the reactive nitrogen species and ROS 
effect in long term chronic inflammation which leads to liver cirrhosis (Wei, CL et al., 2005).   
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